Benzinga
Benzinga
Benzinga
mercoledì, settembre 30

Xeris Biopharma Holdings Inc

XERSNASDAQ
Trade with Public
Trade with Public
$9.56
-0.42-4.21%
In chiusura: Sep 30, 5:00 PM EST
$9.73
0.171.78%
Post-mercato: 4:00 PM EST
PanoramicaNotiziePrevisioni utiliEventiObiettivi di prezzoDati finanziariSentimentAzionariatoConfrontaOpzioniRapporto azionario

Xeris Biopharma Holdings Analyst Price Targets

Wall Street analyst price targets and consensus rating for Xeris Biopharma Holdings (XERS).

Price Target Range — 11 Quarters

Analyst Consensus — 7 Analysts

6Buy
1Hold
Consensus RatingBuy# Analysts7Avg. Consensus PT$11Upside to Avg. PT+14.4%

Rating Trend — Last 9 Months

Recent Analyst Actions

Visualizza tutte le valutazioni →
DateFirmAnalystActionRating ChangePrice Target
Sep 10, 2026Leerink PartnersRoanna RuizPT RaiseOutperform$12→$16
Aug 20, 2026BarclaysGlen SantangeloPT RaiseOverweight$9→$12
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Leerink Partners Maintains Outperform on Xeris Biopharma Holdings, Raises Price Target to $16

Leerink Partners analyst Roanna Ruiz maintains Xeris Biopharma Holdings (NASDAQ:XERS) with a Outperform and raises the price target from $12 to $16.
Benzinga Newsdesk

PRO
Barclays Maintains Overweight on Xeris Biopharma Holdings, Raises Price Target to $12

Barclays analyst Glen Santangelo maintains Xeris Biopharma Holdings (NASDAQ:XERS) with a Overweight and raises the price target from $9 to $12.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Xeris Biopharma Holdings, Maintains $10 Price Target

HC Wainwright & Co. analyst Brandon Folkes reiterates Xeris Biopharma Holdings (NASDAQ:XERS) with a Buy and maintains $10 price target.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Xeris Biopharma Holdings, Maintains $10 Price Target

HC Wainwright & Co. analyst Brandon Folkes reiterates Xeris Biopharma Holdings (NASDAQ:XERS) with a Buy and maintains $10 price target.
Benzinga Newsdesk

PRO
Barclays Initiates Coverage On Xeris Biopharma Holdings with Overweight Rating, Announces Price Target of $9

Barclays analyst Glen Santangelo initiates coverage on Xeris Biopharma Holdings (NASDAQ:XERS) with a Overweight rating and announces Price Target of $9.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Assumes Xeris Biopharma Holdings at Buy, Announces Price Target of $10

HC Wainwright & Co. analyst Brandon Folkes assumes Xeris Biopharma Holdings (NASDAQ:XERS) with a Buy rating and announces Price Target of $10.
Benzinga Newsdesk

Dati e API: API Benzinga · API notizie azionarie · API valutazioni analisti · API logo aziende

Dati di mercato forniti da API Benzinga

Benzinga

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

© 2026 Benzinga | All Rights Reserved